CDK2 and neoplasm: Collectively, our study suggested that STAT3/CDK2/4/6 are important onco-immune signatures that play central roles in tumor progression, tumor immune invasion, poor prognoses, and it’s associated with poor response to immunotherapy; thus, concurrent targeting of this onco-immune signature together with immunotherapy may open up new windows for long-lasting, multilayer tumor control.